Nu Skin Announces Q3 EPS of 34 Cents, Up from 17 Cents Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy NUS?
Q3 Revenue Performance: Nu Skin reported Q3 revenue of $364.211 million, a decrease from $430.145 million in the same quarter last year.
CEO's Statement: CEO Ryan Napierski expressed satisfaction with the results, highlighting alignment with expectations despite a challenging macro environment and the upcoming launch of their intelligent wellness platform.
Regional Growth: The Latin America region showed strong, double-digit year-over-year growth, contributing positively to the overall performance.
Earnings Guidance: The company achieved earnings per share at the high end of their guidance range through disciplined execution and operational efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUS
About NUS
Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nu Skin (NUS) Q1 2026 Earnings Transcript
See More
Nu Skin Enterprises Q1 2026 Earnings Call Insights
- Revenue and Earnings Performance: Nu Skin reported Q1 2026 revenue of $320.6 million with GAAP EPS of $0.04 and adjusted EPS of $0.14, indicating stability during the transformation despite missing expectations.
- Importance of Prysm iO Platform: CEO Napierski emphasized that Prysm iO is not just a product launch but a foundational platform for the company's shift, with over 30,000 devices generating nearly 2 million scans globally, expected to drive subscription revenue growth.
- Future Outlook and Guidance: CFO Lantz maintained the annual guidance, projecting Q2 revenue between $330 million and $360 million and EPS between $0.15 and $0.25, reflecting a cautiously optimistic stance amid macro uncertainties.
- Capital Structure and Shareholder Returns: The company completed refinancing of its credit facilities extending to 2031 and returned approximately $8 million to shareholders, indicating a focus on optimizing capital structure while still prioritizing shareholder value returns.
See More
Nu Skin Launches Prysm iO Intelligent Wellness Platform
- Product Launch: Nu Skin has launched the Prysm iO intelligent nutritional wellness platform in the U.S., which provides personalized feedback on antioxidant levels through a non-invasive skin scan in just 15 seconds, empowering users to better understand how their nutrition supports overall health.
- Technological Innovation: Built on over 20 years of carotenoid research, Prysm iO utilizes patented Spectral Rai technology to capture more than 700,000 hyperspectral absorption measurements during each scan, delivering a scientifically-backed personalized 'Nutrition Health Score'.
- Clinical Validation: Recent clinical studies demonstrate a strong correlation between Prysm iO measurements and blood serum carotenoid levels (R² = 0.75-0.77), confirming its accuracy and consistency across diverse skin types, thereby enhancing user confidence in health decision-making.
- Market Positioning: Now available in the U.S. for $375, Prysm iO signifies Nu Skin's further expansion into the intelligent beauty and wellness sector, aiming to help consumers make more informed health choices through science-backed personalized insights.
See More
Thorne Brand Experiences Rapid Growth Driven by Gen Z
- Revenue Expectations: Thorne is projected to reach $650 million in annual revenue for 2023, driven by the health-conscious focus of Gen Z and millennial consumers, indicating strong appeal in the younger market segment.
- Consumer Growth: The number of direct consumers has surged from 4 million at the end of 2023 to 7 million, fueling a 63% increase in direct sales, demonstrating the brand's expanding influence among younger shoppers.
- Market Trends: The U.S. vitamins and supplements market is expected to reach $125 billion by 2025, with an 11% growth projected by 2027, reflecting a shift towards proactive health management and demand for personalized products among younger consumers.
- Subscription Model: Thorne attracts consumers to subscribe by offering free shipping and a 10% discount on each refill, with about 50% of shoppers under 40 opting for subscriptions despite some hesitation, showcasing the brand's competitive edge in pricing and service.
See More
Nu Skin Appoints Chelsea Lantz as Interim CFO Following Departure of James Thomas
- Executive Change: Nu Skin announced the appointment of Chelsea Lantz as interim CFO, effective immediately following the departure of James Thomas, who left after 16 years with the company to pursue other opportunities, highlighting challenges in executive stability.
- Internal Promotion: Lantz, who joined the company in 2011 and has served as corporate controller since 2023, will take on the interim CFO role, which is expected to support the company's ongoing efforts in operational and balance sheet improvements.
- Formal Search Initiated: Nu Skin has begun a formal search for a permanent CFO, indicating the company's commitment to restructuring its executive team and long-term strategic planning, aiming to ensure continuity and stability in financial management.
- Market Reaction: Following this announcement, Nu Skin's stock price fell 0.14% in after-hours trading to $7.12, reflecting market caution regarding the executive change and potentially impacting investor confidence in the company's future performance.
See More
Nu Skin Appoints Chelsea Lantz as Interim CFO
- Executive Transition: Nu Skin announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately following James Thomas's resignation, demonstrating the company's agility in executive changes.
- Financial Leadership Experience: Lantz has been with Nu Skin since 2011 and has served as corporate controller since 2023, leading cost improvement initiatives that resulted in a significant year-over-year increase in EPS, showcasing her strong financial management background.
- Strategic Transformation: CEO Ryan Napierski stated that Lantz's appointment will drive the company's transformation into a leading intelligent beauty and wellness platform, emphasizing ongoing efforts to enhance operational performance and strengthen the balance sheet.
- Succession Planning Initiated: Nu Skin's board has initiated a formal process to appoint a permanent CFO, reflecting the company's commitment to executive stability and proactive planning for future growth.
See More
Nu Skin (NUS) Q1 2026 Earnings Transcript
See More
Nu Skin Enterprises Q1 2026 Earnings Call Insights
- Revenue and Earnings Performance: Nu Skin reported Q1 2026 revenue of $320.6 million with GAAP EPS of $0.04 and adjusted EPS of $0.14, indicating stability during the transformation despite missing expectations.
- Importance of Prysm iO Platform: CEO Napierski emphasized that Prysm iO is not just a product launch but a foundational platform for the company's shift, with over 30,000 devices generating nearly 2 million scans globally, expected to drive subscription revenue growth.
- Future Outlook and Guidance: CFO Lantz maintained the annual guidance, projecting Q2 revenue between $330 million and $360 million and EPS between $0.15 and $0.25, reflecting a cautiously optimistic stance amid macro uncertainties.
- Capital Structure and Shareholder Returns: The company completed refinancing of its credit facilities extending to 2031 and returned approximately $8 million to shareholders, indicating a focus on optimizing capital structure while still prioritizing shareholder value returns.
See More
Nu Skin Launches Prysm iO Intelligent Wellness Platform
- Product Launch: Nu Skin has launched the Prysm iO intelligent nutritional wellness platform in the U.S., which provides personalized feedback on antioxidant levels through a non-invasive skin scan in just 15 seconds, empowering users to better understand how their nutrition supports overall health.
- Technological Innovation: Built on over 20 years of carotenoid research, Prysm iO utilizes patented Spectral Rai technology to capture more than 700,000 hyperspectral absorption measurements during each scan, delivering a scientifically-backed personalized 'Nutrition Health Score'.
- Clinical Validation: Recent clinical studies demonstrate a strong correlation between Prysm iO measurements and blood serum carotenoid levels (R² = 0.75-0.77), confirming its accuracy and consistency across diverse skin types, thereby enhancing user confidence in health decision-making.
- Market Positioning: Now available in the U.S. for $375, Prysm iO signifies Nu Skin's further expansion into the intelligent beauty and wellness sector, aiming to help consumers make more informed health choices through science-backed personalized insights.
See More
Thorne Brand Experiences Rapid Growth Driven by Gen Z
- Revenue Expectations: Thorne is projected to reach $650 million in annual revenue for 2023, driven by the health-conscious focus of Gen Z and millennial consumers, indicating strong appeal in the younger market segment.
- Consumer Growth: The number of direct consumers has surged from 4 million at the end of 2023 to 7 million, fueling a 63% increase in direct sales, demonstrating the brand's expanding influence among younger shoppers.
- Market Trends: The U.S. vitamins and supplements market is expected to reach $125 billion by 2025, with an 11% growth projected by 2027, reflecting a shift towards proactive health management and demand for personalized products among younger consumers.
- Subscription Model: Thorne attracts consumers to subscribe by offering free shipping and a 10% discount on each refill, with about 50% of shoppers under 40 opting for subscriptions despite some hesitation, showcasing the brand's competitive edge in pricing and service.
See More
Nu Skin Appoints Chelsea Lantz as Interim CFO Following Departure of James Thomas
- Executive Change: Nu Skin announced the appointment of Chelsea Lantz as interim CFO, effective immediately following the departure of James Thomas, who left after 16 years with the company to pursue other opportunities, highlighting challenges in executive stability.
- Internal Promotion: Lantz, who joined the company in 2011 and has served as corporate controller since 2023, will take on the interim CFO role, which is expected to support the company's ongoing efforts in operational and balance sheet improvements.
- Formal Search Initiated: Nu Skin has begun a formal search for a permanent CFO, indicating the company's commitment to restructuring its executive team and long-term strategic planning, aiming to ensure continuity and stability in financial management.
- Market Reaction: Following this announcement, Nu Skin's stock price fell 0.14% in after-hours trading to $7.12, reflecting market caution regarding the executive change and potentially impacting investor confidence in the company's future performance.
See More
Nu Skin Appoints Chelsea Lantz as Interim CFO
- Executive Transition: Nu Skin announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately following James Thomas's resignation, demonstrating the company's agility in executive changes.
- Financial Leadership Experience: Lantz has been with Nu Skin since 2011 and has served as corporate controller since 2023, leading cost improvement initiatives that resulted in a significant year-over-year increase in EPS, showcasing her strong financial management background.
- Strategic Transformation: CEO Ryan Napierski stated that Lantz's appointment will drive the company's transformation into a leading intelligent beauty and wellness platform, emphasizing ongoing efforts to enhance operational performance and strengthen the balance sheet.
- Succession Planning Initiated: Nu Skin's board has initiated a formal process to appoint a permanent CFO, reflecting the company's commitment to executive stability and proactive planning for future growth.
See More
